Background
Crosstalk between inflammation and the immune system plays an important role in tumor malignant progression, immune evasion, and immunotherapy efficacy. This study aims to explore the significance of inflammation-associated gene ribosomal-b…
Background
Current immunotherapy regimens most often fail due to an insufficient T cell response and/or immune-related adverse events (irAEs) which lead to treatment discontinuation. Additionally, many cancers likely require combination immunotherapie…
Abstract
Peptide presentation on human leukocyte antigens (HLAs) is essential for initiating T-cell responses and all consequences of this presentation including anticancer immunity or immune escape. Many studies have relied on in silico prediction to…
Background
The immunonutritional background has been deeply implicated in cancer behavior and clinical outcomes. In this study, we explored the prognostic impact of the Controlling Nutritional Status (CONUT) score through its correlation with blood im…
Immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in patients with advanced malignancies. However, their association with immune thrombocytopenia (ITP) poses a critical risk of severe hemorrhage and necessitates treatme…
Background
The CpG/α-OX40 in situ vaccine strategy has shown efficacy in immune-hot tumors but remains ineffective in immune-cold tumors possibly due to immunosuppressive microenvironments characterized by myeloid-derived suppressor cells (MDSCs…
Background
Despite breakthroughs in immune checkpoint blockade (ICB) for advanced hepatocellular carcinoma (HCC), tumor immune evasion remains a major limitation to immunotherapy efficacy. PTEN-induced putative kinase 1 (PINK1) has highlighted roles i…
Background
Neutralization of interferon (IFN)- abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II but can be ind…
